Clinical Trials Directory

Trials / Unknown

UnknownNCT05923918

A Study to Evaluate Safety and Efficacy of PBK_M2101

A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2101

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
246 (estimated)
Sponsor
Pharmbio Korea Co., Ltd. · Industry
Sex
All
Age
19 Years
Healthy volunteers
Accepted

Summary

This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.

Conditions

Interventions

TypeNameDescription
DRUGPBK_M2101 2-DaySubjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
DRUGPBK_M2101 1-DaySubjects who are randomized into group test 2 will receive bowel preparation on the same-day.
DRUGOral Sulfate Tablet 2-DaySubjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.

Timeline

Start date
2023-06-01
Primary completion
2024-05-01
Completion
2024-06-01
First posted
2023-06-28
Last updated
2023-06-28

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05923918. Inclusion in this directory is not an endorsement.